PRTA - Prothena Corporation plc
| Previous Close | 11.51 |
| Open | 11.41 |
| Bid | 10.29 x 800 |
| Ask | 12.00 x 1200 |
| Day's Range | 10.23 - 11.44 |
| 52 Week Range | 6.71 - 17.63 |
| Volume | 183,716 |
| Avg. Volume | 204,661 |
| Market Cap | 413.083M |
| Beta (5Y Monthly) | 2.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.95 |
| Earnings Date | May 03, 2020 - May 07, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.50 |
- GlobeNewswire
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Prothena Corporation plc (PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced that in connection with hiring an executive on March 30, 2020, the compensation committee of the Company’s board of directors granted the individual hired by Prothena an option to purchase 120,000 shares of the Company’s common stock. The stock option has an exercise price per share equal to $10.99, which was the closing trading price on April 1, 2020, the date of the grant. The stock option was granted pursuant to the Company’s 2020 Employment Inducement Incentive Plan, which was approved by the Company’s board of directors under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
- GlobeNewswire
Baseline Data from Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson’s Disease to be Presented at AAT-AD/PD
Prothena Corporation plc (PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced that baseline data from the Phase 2 PASADENA study of prasinezumab in patients with early Parkinson’s disease will be presented by Roche in an oral presentation at the Advances in Alzheimer’s and Parkinson’s Therapies AAT-AD/PD Focus Meeting (AAT-AD/PD), to be held virtually on April 2-5, 2020. Prasinezumab, a monoclonal antibody under development for the potential treatment of Parkinson's disease, is the focus of a worldwide collaboration between Prothena and Roche. Baseline data from the Phase 2 PASADENA study of prasinezumab in patients with early Parkinson's disease, will be presented in the following virtual oral session.
- Zacks
Prothena (PRTA) Down 24.8% Since Last Earnings Report: Can It Rebound?
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire
Prothena Announces Appointment of Brandon Smith as Chief Business Officer
Prothena Corporation plc (PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced the appointment of Brandon Smith as Chief Business Officer. Mr. Smith will be responsible for leading Prothena’s business development initiatives, portfolio strategic planning and alliance management activities. “Brandon is a proven leader with a diverse experience across multiple sectors of the biotech industry and we are pleased to welcome him to our executive team,” said Gene Kinney, Ph.D., President and Chief Executive Officer of Prothena.
- Thomson Reuters StreetEvents
Edited Transcript of PRTA earnings conference call or presentation 12-Feb-20 9:30pm GMT
Q4 2019 Prothena Corporation PLC Earnings Call
- Zacks
Prothena (PRTA) Q4 Loss Narrower Than Expected, Revenues Beat
Prothena (PRTA) reports a narrower-than-expected Q4 loss, while revenues surpass estimates.
- Zacks
Prothena (PRTA) Reports Q4 Loss, Tops Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of 16.92% and 28.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Prothena Reports Fourth Quarter and Full Year 2019 Financial Results, and Provides Financial Guidance and R&D Update
Net cash used in operating and investing activities was $14.6 million in the fourth quarter and $53.5 million for the full year 2019; quarter-end cash and restricted cash.
- ACCESSWIRE
Prothena Corp. Plc to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 12, 2020 / Prothena Corp. Plc (NASDAQ:PRTA) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 12, 2020 at ...
- GlobeNewswire
Prothena to Report Fourth Quarter and Full Year 2019 Financial Results and Host Webcast Conference Call on February 12
Prothena Corporation plc (PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, announced today that it will report its fourth quarter and full year 2019 financial results on Wednesday, February 12, 2020 after the close of the U.S. financial markets. To access the call via dial-in, please dial (877) 887-5215 (U.S. and Canada toll free) or (315) 625-3069 (international) five minutes prior to the start time and refer to conference ID number 1758808. A replay of the call will be available until February 26, 2020 via dial-in at (855) 859-2056 (U.S. toll free) or (404) 537-3406 (international), Conference ID Number 1758808.
- Simply Wall St.
Imagine Owning Prothena (NASDAQ:PRTA) And Trying To Stomach The 71% Share Price Drop
It is a pleasure to report that the Prothena Corporation plc (NASDAQ:PRTA) is up 55% in the last quarter. But only the...
- Zacks
Options Traders Expect Huge Moves in Prothena (PRTA) Stock
Investors need to pay close attention to Prothena (PRTA) stock based on the movements in the options market lately.
- Insider Monkey
Did Hedge Funds Drop The Ball On Prothena Corporation plc (PRTA) ?
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
- GlobeNewswire
Prothena Announces Appointment of Oleg Nodelman to its Board of Directors
Prothena Corporation plc (PRTA), a clinical-stage neuroscience company, announced today the appointment of Oleg Nodelman to its Board of Directors. “Oleg is a veteran biotechnology investor and advisor with deep roots in the biotechnology and scientific communities,” commented Lars Ekman, Prothena's Chairman.
- Zacks
Why Is Prothena (PRTA) Up 36.1% Since Last Earnings Report?
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
Prothena (NASDAQ:PRTA) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
- Zacks
Prothena (PRTA) Reports Narrower-than-Expected Loss in Q3
Prothena (PRTA) posts a narrower Q3 loss while sales surpass estimates.
- Zacks
Prothena (PRTA) Reports Q3 Loss, Tops Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of 9.26% and 36.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Prothena Reports Third Quarter 2019 Financial Results and Provides R&D Update
Net cash used in operating and investing activities was $9.2 million in the third quarter and $38.9 million for the first nine months of 2019; quarter-end cash and restricted.
- GlobeNewswire
Prothena to Report Third Quarter 2019 Financial Results on November 5
Prothena Corporation plc (PRTA), a clinical-stage neuroscience company, will announce financial results for the third quarter and first nine months of 2019 on November 5, 2019 after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on November 5. Prothena Corporation plc is a clinical-stage neuroscience company focused on the discovery and development of novel therapies with the potential to fundamentally change the course of devastating neurological disorders.
- Zacks
Prothena (PRTA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire
Labaton Sucharow LLP and Levi & Korsinsky LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of Ordinary Shares of Prothena Corporation plc in In re Prothena Corporation plc Securities Litigation, No. 1:18-cv-06425-ALC
To: All persons and entities that purchased or acquired the publicly traded ordinary shares of Prothena Corporation plc during the period from October 15, 2015 through April 20, 2018, inclusive (the "Class Period"), and were allegedly damaged thereby (the "Settlement Class"). YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the Southern District of New York, that Court-appointed Lead Plaintiffs, on behalf of themselves and all members of the proposed Settlement Class, and Prothena Corporation plc ("Prothena" or the "Company"), Dr. Gene Kinney, Tran B. Nguyen, and Dr. Sarah Noonberg, M.D., Ph.D. (the "Defendants"), have reached a proposed settlement of the claims in the above-captioned class action (the "Action") in the amount of $15,750,000 (the "Settlement").
- Simply Wall St.
How Should Investors React To Prothena Corporation plc's (NASDAQ:PRTA) CEO Pay?
Gene Kinney became the CEO of Prothena Corporation plc (NASDAQ:PRTA) in 2016. This analysis aims first to contrast CEO...
- GuruFocus.com
4 Negative Enterprise Value Stocks
Finding stocks with a negative enterprise value is an excellent way to find deep value Continue reading...
